Type 2 diabetes mellitus: What is the optimal treatment regimen?

American Journal of Medicine

Volumn 116, Issue 5 SUPPL. 1, 2004, Pages 23-29

  Bell, David S H ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLUCOSE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; METFORMIN; NATEGLINIDE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ALGORITHM; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DRUG ABSORPTION; DRUG EFFECT; DRUG EXCRETION; EDEMA; ENZYME INHIBITION; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOXEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LACTIC ACIDOSIS; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PERFUSION; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 1542513461     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.10.017     Document Type: Conference Paper

References (46)

1. Chu N.V., Kong A.P., Kim D.D., et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 25:2002;542-549.
2. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest. 106:2000;467-472.
3. Okuno A., Tamemoto H., Tobe K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 101:1998;1354-1361.
4. Guan H.P., Li Y., Jensen M.V., et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med. 8:2002;1122-1128.
5. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.
6. Parulkar A.A., Pendergrass M.L., Granda-Ayala R., et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 134:2001;61-71.
7. Kelly I.E., Han T.S., Walsh K., Lean M.E. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 22:1999;288-293.
8. Frohlich M., Imhof A., Berg G., et al. Association between C-reactive protein and features of the metabolic syndrome a population-based study. Diabetes Care. 23:2000;1835-1839.
9. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40:1997;1286-1292.
10. Law R.E., Goetze S., Xi X.P., et al. Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation. 101:2000;1311-1318.
11. Takagi T., Akasaka T., Yamamuro A., et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus a serial intravascular ultrasound study. J Am Coll Cardiol. 36:2000;1529-1535.
12. Minamikawa J., Tanaka S., Yamauchi M., et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 83:1998;1818-1820.
13. Shimabukuro M., Koyama K., Chen G., et al. Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci U S A. 94:1997;4637-4641.
14. Shimabukuro M., Ohneda M., Lee Y., Unger R.H. Role of nitric oxide in obesity-induced β cell disease. J Clin Invest. 100:1997;290-295.
15. Finegood D.T., McArthur M.D., Kojwang D., et al. β-cell mass dynamics in Zucker diabetic fatty rats rosiglitazone prevents the rise in net cell death. Diabetes. 50:2001;1021-1029.
16. Porter L.E., Freed M.I., Jones M.P., Biswas N. Rosiglitazone improves β-cell mass dynamic in Zucker diabetic fatty rats rosiglitazone prevents the rise in net cell death. Diabetes. 49:2000;A122.
17. Ovalle F., Bell D.S. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 4:2002;56-59.
18. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 51:2002;2796-2803.
19. Tang W.H., Francis G.S., Hoogwerf B.J., Yong J.B. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 41:2003;1394-1398.
20. Bell D.S. Heart failure the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 26:2003;2433-2441.
21. Bell D.S. Why I initiate therapy with two insulin sensitizers in the type 2 diabetic patient. Endocr Pract. 9:2003;98-100.
22. Masoudi F.A., Wang Y., Inzucchi S.E., et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 290:2003;81-85.
23. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) prospective observational study. BMJ. 321:2000;405-412.
24. Khaw K.T., Wareham N., Luben R., et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 322:2001;15-18.
25. American Diabetes Association. Reducing cardiac mortality in patients with diabetes: perspectives from the 59th Scientific Sessions of the American Diabetes Association. American Diabetes Association, Baylor College of Medicine; Dallas, TX; 1999.
26. Geiss LS, Herman WH, Smith PJ. Mortality in non-insulin dependent diabetes. In: National Diabetes Data Group, ed. Diabetes in America. 2nd ed. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 1995:233-257. NIH publication 95-1468
27. Ovalle F., Bell D.S. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract. 4:1998;146-147.
28. Bell D.S., Ovalle F., Shadmany S. Conversion from troglitazone to rosiglitazone. Endocr Pract. 7:2001;326.
29. Bell D.S., Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 8:2002;271-275.
30. Ovalle F, Bell DSH. The effect of rosiglitazone versus insulin on the pancreatic beta-cell function of patients with type-2 diabetes mellitus. Diabetes. In press
31. Lebovitz H.E. A new oral therapy for diabetes management α-glucosidase inhibition with acarbose. Clin Diabetes. 13:1995;99-103.
32. Chiasson J.L., Josse R.G., Hunt J.A., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus a multicenter controlled clinical trial. Ann Intern Med. 121:1994;928-935.
33. Segal P., Feig P.U., Schernthaner G., et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 20:1997;687-691.
34. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance the STOP-NIDDM trial. JAMA. 290:2003;486-494.
35. Precose® (acarbose tablets) [prescribing information]; West Haven, CT: Bayer Pharmaceuticals Corp; 2003.
36. Bell D.S. Deja vu all over again? University Group Diabetes Program. Endocr Pract. 4:1998;64-65.
37. Perfetti R., Ahmad A. Novel sulfonylurea and non-sulfonylurea drugs to promote the secretion of insulin. Trends Endocrinol Metab. 11:2000;218-223.
38. Bell D.S.H., Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Pract. 3:1997;281-283.
39. ter Braak E.W., Appelman A.M., van der Tweel I., et al. The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care. 25:2002;107-112.
40. Garratt K.N., Brady P.A., Hassinger N.L., et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 33:1999;119-124.
41. Scognamiglio R., Avogaro A., Vigili dK., et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia- induced myocardial dysfunction in type 2 diabetes. Diabetes. 51:2002;808-812.
42. Klepzig H., Kober G., Matter C., et al. Sulfonylureas and ischaemic preconditioning a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 20:1999;439-446.
43. Lee T.M., Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 88:2003;531-537.
44. Huizar J.F., Gonzalez L.A., Alderman J., Smith H.S. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol. 42:2003;1017-1021.
45. Yki-Jarvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 23:2000;1130-1136.
46. Aviles-Santa L., Sinding J., Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 131:1999;182-188.